Definitive Contract 75N93022C00025
Award Date
7/1/22
Potential Completion Date
6/30/23
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Tetracore, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $1,488,107.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Tetracore, Inc., a small business based in Rockville, Maryland. The contract is for the Phase II development of a rapid molecular assay for the point-of-care detection of Treponema pallidum, the causative agent of syphilis. This contract was awarded under the Small Business Innovation...
This is a firm fixed-price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services, to Ai Biosciences, Inc., a small disadvantaged business, through the Small Business Innovation Research (SBIR) program. The contract is for the development of a point-of-care diagnostic test to detect gonorrhea and determine antimicrobial susceptibility. The potential value of the contract is $299,652.00, and the period of performance runs from August 8,...
This is a federal contract award to the University of Maryland, Baltimore (UMB) for a Fiscal Year 2022 Broad Agency Announcement (BAA) Topic 18.2 focused on work related to the molecular detection of Treponema pallidum, the causative agent of syphilis. The $2,239,558.00 cost-no-fee contract was awarded on September 30, 2022 by the Centers for Disease Control and Prevention (CDC) and has an ultimate completion date of April 22, 2025. The contract does not have a set-aside designation. Key aspects...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Kephera Diagnostics LLC, a for-profit limited liability company, to develop a biomarker-based test of cure (TOC) to evaluate treatment outcome during the chronic phase of Chagas infection. The contract, a Definitive Contract with Firm Fixed Price pricing, has a potential value of $300,000.00 and a...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase I action contract to Visby Medical, Inc., a for-profit medical diagnostics manufacturer. The $140,000.00 firm-fixed-price contract, which was set aside for small businesses, is for the development of a rapid, accurate point-of-care diagnostic test under SBIR Topic 075. Visby Medical has received...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Qoolabs Inc., a self-certified small disadvantaged business, to develop rapid point-of-care detection tests for serologic status of individuals for cytomegalovirus (CMV) and herpes simplex virus (HSV) infections. The $225,000.00 fixed-price contract has a period of performance through July 31, 2018,...
<p>This is a firm fixed-price contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to B & W TEK Inc., a for-profit manufacturer, for Phase I of the Small Business Innovation Research (SBIR) Topic 073 project titled "Mobile Health Point-of-Care Diagnostics for Tuberculosis". The total contract value is $299,757, and the performance location is Newark, Delaware. The contract is set aside for small businesses.</p>
This is a $454,183 firm fixed-price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, which is set aside for small businesses, is for the development of a rapid at-home test to detect prostate-specific antigen using self-collected finger stick blood. This contract was awarded under the NCI's Small Business...
Immuno Mycologies Inc. was awarded a $299,593 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop an easy-to-use diagnostic test capable of early, rapid detection of Talaromyces antigen in human serum, plasma, and/or urine. This contract was awarded under the Small Business Innovation Research Program Phase I solicitation issued by NIH and the Centers for Disease Control and Prevention seeking proposals to...